Creating an arsenal of Adeno-associated virus (AAV) gene delivery stealth vehicles.
The Adeno-associated virus (AAV) gene delivery system is ushering in a new and exciting era in the United States; following the first approved gene therapy (Glybera) in Europe, the FDA has approved a second therapy, Luxturna [1]. However, challenges to this system remain. In viral gene therapy, the...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-05-01
|
| Series: | PLoS Pathogens |
| Online Access: | http://europepmc.org/articles/PMC5933702?pdf=render |